Analysis of Novel Prostate Cancer Biomarkers and Their Predictive Utility in an Active Surveillance Protocol
Abstract
The Research Project supported by this DOD PCRP Physician Research Training Award investigates novel biomarkers for prostate cancer and investigation of Active Surveillance of low risk prostate cancer. In this fifth year of my DOD PCRP PRTA, I have continued my productivity from both a translational laboratory and clinical research standpoint. We have continued to investigate our list of biologically relevant candidate prostate cancer biomarkers and have demonstrated promising results. We have also continued to investigate the expression of these markers in prostate cancer tissue and normal prostate using immunohistochemistry. We have had promising results with Tissue Inhibitor of Matrix Metalloproteinase Type 1 (TIMP-1), Semenogelin-2, and Leukocyte Elastase Inhibitor (SERPINB1). With these three biomarkers we have made significant strides in identifying differential expression patterns. In addition to success in our laboratory work, we have also continued to make significant accomplishments in analyzing our database of 469 men on active surveillance for prostate cancer over the past 15 years. Our analysis of this database has demonstrated freedom from intervention of 77% at 5 years and 62% at 10 years. Cancer specific survival was 100% at 10 years and overall survival was 95% at 5 years and 88% at 10 years. We are currently in the process of writing a manuscript to formally publish our results.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2016
- Accession Number
- AD1035556
Entities
People
- Adam S. Feldman
Organizations
- Massachusetts General Hospital